Similar studies for GEO DataSets (Select 3721) - GEO DataSets

Select item 37211.

Pretreatment breast needle biopsies of locally advanced breast cancer

Analysis of pretreatment breast cancer (BC) tumors from patients enrolled in a paclitaxel/radiation clinical trial. Patients achieved pathologic complete response (pCR) or partial response (pPR). Results provide insight into molecular markers of pathologic response to paclitaxel/RT treatment of BC.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 2 disease state sets

Platform:: GPL570
Series:: GSE22513
28 Samples

Download data: CEL

DataSet

Accession:: GDS3721

ID:: 3721

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 2000288212.

Laser-capture microdissected invasive micropapillary carcinomas of the breast

(Submitter supplied) The purpose of this study was to identify differentially expressed genes in laser-capture microdissected (LCM) invasive mammary carcinomas (IMCs).

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
89 Samples

Download data: CEL

Series

Accession:: GSE28821

ID:: 200028821

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000287963.

Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers

(Submitter supplied) The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant dose-dense docetaxel treatment using gene expression profiling on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with 75 mg/m2 IV of docetaxel on day 1 of each cycle every 2 weeks x 4 cycles . Tumor tissue from pretreatment biopsies was obtained from 12 patients enrolled in the study. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
24 Samples

Download data: CEL

Series

Accession:: GSE28796

ID:: 200028796

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000225134.

Markers of Taxane Sensitivity in Breast Cancer

(Submitter supplied) The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant paclitaxel/radiation treatment, protein and gene expression profiling were done on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with three cycles of paclitaxel followed by concurrent paclitaxel/radiation. Tumor tissue from pretreatment biopsies was obtained from 19 of the 38 patients enrolled in the study. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS3721
Platform:: GPL570
28 Samples

Download data: CEL

Series

Accession:: GSE22513

ID:: 200022513

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2002069125.

Identification of a minimum number of genes to predict triple negative breast cancer subgroups from gene expression profiles

(Submitter supplied) Background: Triple-negative breast cancer (TNBC) is a very heterogeneous disease. Several gene expression and mutation profiling approaches were used to classify it and all converged to the identification of distinct molecular subtypes, with some overlapping across different approaches. However, a standardised tool to routinely classify TNBC in the clinics and guide personalised treatment is lacking. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL21185
72 Samples

Download data: TXT

Series

Accession:: GSE206912

ID:: 200206912

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000957006.

Molecular subtyping of Triple negative Breast Cancer from Taiwanese

(Submitter supplied) 'Precision medicine' is a concept that by utilizing modern molecular diagnostics, an effective therapy is accurately applied for each cancer patient to improve their survival rates. The aim of this study was to compare the molecular subtypes of triple negative breast cancer (TNBC) between Taiwanese and other datasets.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
57 Samples

Download data: CEL, TXT

Series

Accession:: GSE95700

ID:: 200095700

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000818387.

Gene expression anlaysis of laser-capture microdissected tumor and stroma from triple negative breast cancer

(Submitter supplied) LCM was perfomed on adjacent tumor and stromal cells to identify differentially expressed genes in triple negative breast cancer.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6244
20 Samples

Download data: CEL

Series

Accession:: GSE81838

ID:: 200081838

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000227968.

Specific kinesin expression profiles associated with taxane resistance in breast cancer

(Submitter supplied) Purpose: Breast cancer is a genetically heterogenous disease with subtypes differing in prognosis and chemosensitivity. The basal-like breast cancer (BLBC) molecular subtype is associated with poorer outcomes, but is more responsive to taxane-based chemotherapy. We evaluated the role of kinesins, motor proteins interacting with microtubules, in influencing taxane resistance. Experimental Design: Kinesin (KIF) expression was studied in one local dataset comprising all taxane resistant breast cancers in relation to taxane resistance. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6883
24 Samples

Download data: TXT

Series

Accession:: GSE22796

ID:: 200022796

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000003509.

Sensitive

(Submitter supplied) These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor. Keywords: repeat sample

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL8300
10 Samples

Download data: CEL

Series

Accession:: GSE350

ID:: 200000350

Select item 20000034910.

Resistant

(Submitter supplied) These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Keywords: repeat sample

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL8300
14 Samples

Download data: CEL

Series

Accession:: GSE349

ID:: 200000349

Select item 20004199811.

Biomarker analysis of neoadjuvant Doxorubicin/Cyclophosphamide followed by Ixabepilone or Paclitaxel in early-stage breast cancer

(Submitter supplied) A randomized, open-label, multicenter, phase II trial (NCT00455533) enrolled previously untreated women with histologically-confirmed primary invasive breast adenocarcinoma (T2–3, N0–3, M0, tumor size ≥2.0 cm), regardless of hormone receptor or HER2 expression status. Patients received sequential neoadjuvant therapy starting with 4 cycles of AC (doxorubicin 60 mg/m2 intravenously and cyclophosphamide 600 mg/m2 intravenously) given every 3 weeks, followed by 1:1 randomization to either ixabepilone (40 mg/m2 3-hour infusion) every 3 weeks for 4 cycles, or paclitaxel (80 mg/m2 1-hour infusion) weekly for 12 weeks. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL571
279 Samples

Download data: CEL

Series

Accession:: GSE41998

ID:: 200041998

Select item 20024555412.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype [MDA-MB-453]

(Submitter supplied) Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with no targeted therapeutics. The luminal androgen receptor (LAR), one of the six TNBC subtypes, constitutes 15% of TNBC and is enriched for AR and AR-target genes. Here, we show that a cohort of TNBC not only expresses full-length AR (AR-FL) at a much higher rate (~80%) than previously reported, but also expresses AR splice variants (AR-SVs) (~20%), subclassifying the LAR-TNBC subtype into LAR-FL, LAR-AR-SV, or dual positive. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL30173
6 Samples

Download data: CSV

Series

Accession:: GSE245554

ID:: 200245554

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20024520213.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype [Spacial]

(Submitter supplied) Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with no targeted therapeutics. The luminal androgen receptor (LAR), one of the six TNBC subtypes, constitutes 15% of TNBC and is enriched for AR and AR-target genes. Here, we show that a cohort of TNBC not only expresses full-length AR (AR-FL) at a much higher rate (~80%) than previously reported, but also expresses AR splice variants (AR-SVs) (~20%), subclassifying the LAR-TNBC subtype into LAR-FL, LAR-AR-SV, or dual positive. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
6 Samples

Download data: XLSX

Series

Accession:: GSE245202

ID:: 200245202

PubMed Full text in PMC Similar studies

Select item 20024428314.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL30173 GPL24676
58 Samples

Download data

Series

Accession:: GSE244283

ID:: 200244283

PubMed Full text in PMC Similar studies

Select item 20024428215.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype [project4]

(Submitter supplied) Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with no targeted therapeutics. The luminal androgen receptor (LAR), one of the six TNBC subtypes, constitutes 15% of TNBC and is enriched for AR and AR-target genes. Here, we show that a cohort of TNBC not only expresses full-length AR (AR-FL) at a much higher rate (~80%) than previously reported, but also expresses AR splice variants (AR-SVs) (~20%), subclassifying the LAR-TNBC subtype into LAR-FL, LAR-AR-SV, or dual positive. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL30173
6 Samples

Download data: XLSX

Series

Accession:: GSE244282

ID:: 200244282

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20024427216.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype [project3]

(Submitter supplied) Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with no targeted therapeutics. The luminal androgen receptor (LAR), one of the six TNBC subtypes, constitutes 15% of TNBC and is enriched for AR and AR-target genes. Here, we show that a cohort of TNBC not only expresses full-length AR (AR-FL) at a much higher rate (~80%) than previously reported, but also expresses AR splice variants (AR-SVs) (~20%), subclassifying the LAR-TNBC subtype into LAR-FL, LAR-AR-SV, or dual positive. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
11 Samples

Download data: XLSX

Series

Accession:: GSE244272

ID:: 200244272

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20024427117.

Identification of a Therapeutically Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype [project2]

(Submitter supplied) Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with no targeted therapeutics. The luminal androgen receptor (LAR), one of the six TNBC subtypes, constitutes 15% of TNBC and is enriched for AR and AR-target genes. Here, we show that a cohort of TNBC not only expresses full-length AR (AR-FL) at a much higher rate (~80%) than previously reported, but also expresses AR splice variants (AR-SVs) (~20%), subclassifying the LAR-TNBC subtype into LAR-FL, LAR-AR-SV, or dual positive. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
41 Samples

Download data: XLSX

Series

Accession:: GSE244271

ID:: 200244271

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20005475618.

Expression data from TGFBR3 controls and TGFBR3 knockdown of SUM159 3D cultures

(Submitter supplied) The objective of this experiment was to determine global gene expression change in triple negative cell line upon knockdown of TGFBR3. Genotype specific differences in expression profiles have been evaluated using human HuGene1.0-ST affymetrix array. RNA was extracted from SUM159 controls and SUM159 TGFBR3KD cells cultured in 3-dimensional in vitro system.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6244
6 Samples

Download data: CEL

Series

Accession:: GSE54756

ID:: 200054756

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20007633919.

Identification of four subtypes of Triple Negative Breast Cancer (TNBC) by genomic profiling

(Submitter supplied) The aggressive triple negative breast cancers (TNBCs), which lack estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), comprise a high-risk subset of human breast cancers which remain poorly characterized and lack effective treatments. While meta-analyses have recently suggested the complexity of these tumors, no robust phenotypes have been defined. more...